MX374385B - Apilimod para uso en el tratamiento de melanoma. - Google Patents

Apilimod para uso en el tratamiento de melanoma.

Info

Publication number
MX374385B
MX374385B MX2017006019A MX2017006019A MX374385B MX 374385 B MX374385 B MX 374385B MX 2017006019 A MX2017006019 A MX 2017006019A MX 2017006019 A MX2017006019 A MX 2017006019A MX 374385 B MX374385 B MX 374385B
Authority
MX
Mexico
Prior art keywords
apilimod
melanoma
treatment
methods
relates
Prior art date
Application number
MX2017006019A
Other languages
English (en)
Spanish (es)
Other versions
MX2017006019A (es
Inventor
Chris Conrad
Henri Lichenstein
Jonathan M Rothberg
Neil Beeharry
Paul Beckett
Sean Landrette
Sophia Gayle
Tian Xu
Original Assignee
Ai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ai Therapeutics Inc filed Critical Ai Therapeutics Inc
Publication of MX2017006019A publication Critical patent/MX2017006019A/es
Publication of MX374385B publication Critical patent/MX374385B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2017006019A 2014-11-07 2015-11-06 Apilimod para uso en el tratamiento de melanoma. MX374385B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462077127P 2014-11-07 2014-11-07
US201562115228P 2015-02-12 2015-02-12
US201562119540P 2015-02-23 2015-02-23
PCT/US2015/059502 WO2016073871A1 (en) 2014-11-07 2015-11-06 Apilimod for use in the treatment of melanoma

Publications (2)

Publication Number Publication Date
MX2017006019A MX2017006019A (es) 2017-09-13
MX374385B true MX374385B (es) 2025-03-06

Family

ID=54548301

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017006019A MX374385B (es) 2014-11-07 2015-11-06 Apilimod para uso en el tratamiento de melanoma.
MX2017006026A MX2017006026A (es) 2014-11-07 2015-11-06 Apilimod para uso en el tratamiento de cancer colorrectal.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017006026A MX2017006026A (es) 2014-11-07 2015-11-06 Apilimod para uso en el tratamiento de cancer colorrectal.

Country Status (16)

Country Link
US (2) US20190209576A1 (enExample)
EP (3) EP3215157B8 (enExample)
JP (2) JP6768682B2 (enExample)
KR (2) KR20170098813A (enExample)
CN (2) CN107427522B (enExample)
AU (2) AU2015342876B2 (enExample)
BR (2) BR112017009000A2 (enExample)
CA (2) CA2966334A1 (enExample)
ES (1) ES2734081T3 (enExample)
HU (1) HUE044153T2 (enExample)
IL (2) IL251904B (enExample)
MX (2) MX374385B (enExample)
PL (1) PL3215157T3 (enExample)
PT (1) PT3215157T (enExample)
RU (2) RU2731908C2 (enExample)
WO (2) WO2016073871A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016134406A (ru) 2014-01-24 2018-03-01 Лэм Терапьютикс, Инк. Композиции апилимода и способы их применения
GB201408100D0 (en) * 2014-05-07 2014-06-18 Sec Dep For Health The Detection method
US10206910B2 (en) 2014-11-07 2019-02-19 Lam Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
BR112018009738A2 (pt) * 2016-01-21 2018-12-04 Lam Therapeutics Inc biomarcadores para tratamento contra o câncer com apilimod
RU2019113752A (ru) * 2016-10-12 2020-11-13 ЭйАй ТЕРАПЬЮТИКС, ИНК. Композиции апилимода и способы их применения при лечении болезни альцгеймера
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
AU2019223014B2 (en) 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents
US12589097B2 (en) 2018-02-21 2026-03-31 OrphAl Therapeutics Inc. Apilimod compositions and methods of use
CA3167339A1 (en) 2020-01-13 2021-07-22 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
IL309143A (en) * 2021-06-11 2024-02-01 Orphai Therapeutics Inc Stabilized apilimod compositions and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693097B2 (en) * 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
WO2005076843A2 (en) 2004-02-06 2005-08-25 Elan Pharmaceuticals, Inc. Methods and compositions for treating tumors and metastatic disease
US7745436B2 (en) * 2004-04-13 2010-06-29 Synta Pharmaceuticals Corporation Disalt inhibitors of IL-12 production
WO2006029385A2 (en) 2004-09-08 2006-03-16 Chelsea Therapeutics, Inc. Quinazoline derivatives as metabolically inert antifolate compounds.
WO2006053112A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Process for preparing trisubstituted pyrimidine compounds
US7863270B2 (en) * 2005-05-13 2011-01-04 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
ES2436877T3 (es) 2005-11-17 2014-01-07 OSI Pharmaceuticals, LLC Intermedios para la preparación de inhibidores de mTOR bicíclicos condensados
HUE032274T2 (en) 2006-07-12 2017-09-28 Univ Tennessee Res Found Substituted acetanilides and methods of their application
RU2438664C2 (ru) * 2007-05-15 2012-01-10 Пирамал Лайф Сайнсиз Лимитед Синергическая фармацевтическая комбинация для лечения рака
US8402515B2 (en) 2010-05-06 2013-03-19 Jonathan Weizman Apparatus and method for establishing a peer-to-peer communication session with a client device
WO2011146727A1 (en) * 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9295731B2 (en) * 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
RU2016134406A (ru) * 2014-01-24 2018-03-01 Лэм Терапьютикс, Инк. Композиции апилимода и способы их применения
US10206910B2 (en) * 2014-11-07 2019-02-19 Lam Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
EP3253389A4 (en) * 2015-02-03 2018-07-18 LAM Therapeutics, Inc. Apilimod compositions and methods for using same
US20180078561A1 (en) * 2015-03-31 2018-03-22 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
TWI746449B (zh) * 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法

Also Published As

Publication number Publication date
EP3215157B1 (en) 2019-04-10
RU2731908C2 (ru) 2020-09-09
RU2739992C2 (ru) 2020-12-30
EP3215159B1 (en) 2021-07-21
IL251903A0 (en) 2017-06-29
US20170333439A1 (en) 2017-11-23
MX2017006019A (es) 2017-09-13
JP2017535600A (ja) 2017-11-30
PL3215157T3 (pl) 2019-11-29
US10765682B2 (en) 2020-09-08
EP3215157B8 (en) 2019-05-22
KR20170098813A (ko) 2017-08-30
KR20170101907A (ko) 2017-09-06
RU2017119064A (ru) 2018-12-10
IL251903B (en) 2021-05-31
HUE044153T2 (hu) 2019-09-30
CA2966334A1 (en) 2016-05-12
RU2017119066A3 (enExample) 2019-06-07
EP3215159A1 (en) 2017-09-13
MX2017006026A (es) 2017-06-19
CN107427522B (zh) 2021-06-15
AU2015342863B2 (en) 2021-01-21
JP2017533963A (ja) 2017-11-16
RU2017119066A (ru) 2018-12-07
PT3215157T (pt) 2019-07-12
ES2734081T3 (es) 2019-12-04
AU2015342876A1 (en) 2017-06-15
JP6716585B2 (ja) 2020-07-01
RU2017119064A3 (enExample) 2019-06-03
EP3215157A1 (en) 2017-09-13
BR112017009000A2 (pt) 2017-12-19
CN107427522A (zh) 2017-12-01
IL251904A0 (en) 2017-06-29
WO2016073871A1 (en) 2016-05-12
IL251904B (en) 2021-03-25
AU2015342876B2 (en) 2020-07-09
CA2966356A1 (en) 2016-05-12
EP3954375A1 (en) 2022-02-16
AU2015342863A1 (en) 2017-06-15
CN107206090A (zh) 2017-09-26
JP6768682B2 (ja) 2020-10-14
WO2016073884A1 (en) 2016-05-12
BR112017009265A2 (pt) 2017-12-19
US20190209576A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
BR112017006664A2 (pt) terapias de combinação
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
PL3206497T3 (pl) Kompozycje i sposoby leczenia zaburzeń czynności gruczołu Meiboma
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX381544B (es) Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
MX379126B (es) Formulación de factor viii.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
PL3373922T3 (pl) Kompozycje i sposoby do stosowania do leczenia homocystynurii
PH12016501838A1 (en) Compounds and their methods of use
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
MX385322B (es) Uso de sedoheptulosa para la prevención y tratamiento de inflamación.
MX2017011904A (es) Composiciones para el tratamiento de fibrosis y afecciones relacionadas con fibrosis.
MX2016011416A (es) Composiciones de glicoproteinas sialiladas y usos de estas.

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: LUTRON TECHNOLOGY COMPANY LLC